p53 downregulates Down syndrome-associated DYRK1A through miR-1246.

EMBO Rep

Department of Biochemistry & Molecular Biology, Indiana University School of Medicine-Simon Cancer Center, 635 Barnhill Drive, MS4053, Indianapolis, Indiana 46202, USA.

Published: June 2011

Several microRNAs mediate the functions of p53 family members. Here we characterize miR-1246 as a new target of this family. In response to DNA damage, p53 induces the expression of miR-1246 which, in turn, reduces the level of DYRK1A, a Down syndrome-associated protein kinase. Knockdown of p53 has the opposite effect. Overexpression of miR-1246 reduces DYRK1A levels and leads to the nuclear retention of NFATc1, a protein substrate of DYRK1A, and the induction of apoptosis, whereas a miR-1246-specific inhibitor prevented the nuclear import of NFATc1. Together, these results indicate that p53 inhibits DYRK1A expression through the induction of miR-1246.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147276PMC
http://dx.doi.org/10.1038/embor.2011.98DOI Listing

Publication Analysis

Top Keywords

p53
5
dyrk1a
5
mir-1246
5
p53 downregulates
4
downregulates syndrome-associated
4
syndrome-associated dyrk1a
4
dyrk1a mir-1246
4
mir-1246 micrornas
4
micrornas mediate
4
mediate functions
4

Similar Publications

SIRT6 is known to play a protective role in several kidney diseases; however, its role in vancomycin-induced renal injury remains unclear. This study aims to confirm the role and related mechanisms of SIRT6 in vancomycin-induced renal injury. To develop a kidney damage model, mice were given vancomycin injections for seven days.

View Article and Find Full Text PDF

Cadmium (Cd), one of the toxic heavy metals, is of great importance for public health due to its use in many industrial areas. Propolis is a natural product with antioxidant and anti-inflammatory properties collected from plants by honey bees. The aim of this study was to investigate the protective role of propolis against the potential toxic effects of cadmium chloride in blood, liver and kidney tissues.

View Article and Find Full Text PDF

Immunomodulatory lectin from Cordia myxa targets PI3K/AKT signalling mediated apoptosis to regress both in-vitro and in-vivo tumour.

Int J Biol Macromol

January 2025

Molecular Biomedicine Laboratory, Postgraduate Department of Studies and Research in Biotechnology, Sahyadri Science College, Kuvempu University, Shivamogga, Karnataka, India. Electronic address:

Plant based medicine is gaining recognition as a complementary approach to conventional treatments. Plants contain lectins that bind to carbohydrates and exhibit various biological properties and being used in cancer treatment. In present investigation Cordia myxa fruit was chosen, screen for presence of lectin and explore its biological role.

View Article and Find Full Text PDF

Lactate shuttling links histone lactylation to adult hippocampal neurogenesis in mice.

Dev Cell

January 2025

State Key Laboratory for Molecular and Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100093, China. Electronic address:

Lactate has emerged as a central metabolic fuel and an important signaling molecule. Its availability participates in various brain functions. Although lactate homeostasis is vital for adult hippocampal neurogenesis and cognition, it is still unknown how shuttles lactate across the plasma membrane of neural stem cells (NSCs) to control their activity and neurogenic potential.

View Article and Find Full Text PDF

Structure-based design of new anticancer N3-Substituted quinazolin-4-ones as type I ATP-competitive inhibitors targeting the deep hydrophobic pocket of EGFR.

Comput Biol Med

January 2025

Drug Design and Discovery Lab, Helmy Institute of Medical Sciences, Zewail City of Science, Technology and Innovation, Giza, 12578, Egypt; Biomedical Sciences Program, University of Science and Technology, Zewail City of Science, Technology and Innovation, Giza, 12578, Egypt. Electronic address:

Epidermal growth factor receptor (EGFR) is amongst the earliest targeted kinases by small-molecule inhibitors for the management of EGFR-positive cancer types. While a few inhibitors are granted FDA approval for clinical use, discovery of new inhibitors is still of merit to enhance ligand-binding stability and subsequent enzyme inhibition. Thus, a structure-based design approach was adopted to devise a new series of twenty-nine N3-substituted quinazolin-4-ones as type I ATP-competitive inhibitors targeting the deep hydrophobic pocket of EGFR.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!